JP2018512151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512151A5 JP2018512151A5 JP2017553119A JP2017553119A JP2018512151A5 JP 2018512151 A5 JP2018512151 A5 JP 2018512151A5 JP 2017553119 A JP2017553119 A JP 2017553119A JP 2017553119 A JP2017553119 A JP 2017553119A JP 2018512151 A5 JP2018512151 A5 JP 2018512151A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- mutein
- human
- cells
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 21
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 108010002350 Interleukin-2 Proteins 0.000 claims 9
- 102000000588 Interleukin-2 Human genes 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 210000003289 regulatory T cell Anatomy 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- 102200105319 rs397514675 Human genes 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 102220595293 Minor histocompatibility protein HB-1_H16Y_mutation Human genes 0.000 claims 3
- 102220546830 Nuclear pore complex protein Nup85_L19A_mutation Human genes 0.000 claims 3
- 102220472091 Protein ENL_D20T_mutation Human genes 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 102220110995 rs115116507 Human genes 0.000 claims 3
- 102220579314 ARF GTPase-activating protein GIT1_L12S_mutation Human genes 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000012657 Atopic disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 102220638990 Beta-enolase_H16A_mutation Human genes 0.000 claims 2
- 102220638992 Beta-enolase_H16D_mutation Human genes 0.000 claims 2
- 102220638984 Beta-enolase_H16K_mutation Human genes 0.000 claims 2
- 102220638986 Beta-enolase_H16S_mutation Human genes 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102220546836 Nuclear pore complex protein Nup85_L19D_mutation Human genes 0.000 claims 2
- 102220550572 Proteasome maturation protein_L19E_mutation Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 208000024711 extrinsic asthma Diseases 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 102200000390 rs121917859 Human genes 0.000 claims 2
- 102200066678 rs1554618767 Human genes 0.000 claims 2
- 102220112880 rs370986101 Human genes 0.000 claims 2
- 102220013748 rs397516745 Human genes 0.000 claims 2
- 102220120718 rs886042647 Human genes 0.000 claims 2
- 208000000995 spontaneous abortion Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102220626060 HMG box transcription factor BBX_D84A_mutation Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 102220479935 Leucine-rich repeat-containing protein 26_R81A_mutation Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102220595270 Minor histocompatibility protein HB-1_H16R_mutation Human genes 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102220640550 Putative oxidoreductase GLYR1_L19S_mutation Human genes 0.000 claims 1
- 102220351326 c.35T>A Human genes 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 102000055277 human IL2 Human genes 0.000 claims 1
- 238000011577 humanized mouse model Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102200068760 rs1805006 Human genes 0.000 claims 1
- 102200139516 rs35960830 Human genes 0.000 claims 1
- 102220105333 rs730882078 Human genes 0.000 claims 1
- 102220217104 rs779385322 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021096449A JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
| JP2023106755A JP7649349B2 (ja) | 2016-05-04 | 2023-06-29 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/030843 WO2016164937A2 (en) | 2015-04-10 | 2016-05-04 | Interleukin-2 muteins for the expansion of t-regulatory cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096449A Division JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512151A JP2018512151A (ja) | 2018-05-17 |
| JP2018512151A5 true JP2018512151A5 (enExample) | 2019-06-06 |
| JP7422480B2 JP7422480B2 (ja) | 2024-01-26 |
Family
ID=61598336
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553119A Active JP7422480B2 (ja) | 2016-05-04 | 2016-05-04 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| JP2021096449A Pending JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
| JP2023106755A Active JP7649349B2 (ja) | 2016-05-04 | 2023-06-29 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096449A Pending JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
| JP2023106755A Active JP7649349B2 (ja) | 2016-05-04 | 2023-06-29 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP3280725B1 (enExample) |
| JP (3) | JP7422480B2 (enExample) |
| KR (3) | KR20240115933A (enExample) |
| CN (2) | CN115073581A (enExample) |
| NZ (1) | NZ775714A (enExample) |
| WO (1) | WO2016164937A2 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105121715B (zh) | 2012-12-11 | 2018-10-26 | 艾伯特叶史瓦大学爱因斯坦医学院 | 高通量受体:配体鉴定方法 |
| EP3875152B1 (en) | 2014-12-15 | 2024-04-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| CN117659160A (zh) * | 2015-09-11 | 2024-03-08 | 小利兰·斯坦福大学托管委员会 | 生物相关正交细胞因子/受体对 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3411414A4 (en) | 2016-02-05 | 2019-10-23 | Washington University | COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF |
| CA3022331A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| CN109475628A (zh) | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| EP3475413B1 (en) * | 2016-06-22 | 2024-02-14 | David Klatzmann | Genetically modified t lymphocytes |
| CN110167957A (zh) * | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| WO2019112852A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US20200181220A1 (en) * | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
| WO2019051127A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| JP2021500855A (ja) * | 2017-09-07 | 2021-01-14 | キュー バイオファーマ， インコーポレイテッド | 抗原提示ポリペプチドおよびその使用方法 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3083941A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Il-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| AU2018394189B2 (en) * | 2017-12-27 | 2023-12-21 | Kyowa Kirin Co., Ltd. | IL-2 variant |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| JP7534215B2 (ja) | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| US11359000B2 (en) | 2018-03-28 | 2022-06-14 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
| WO2019246404A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| DK4186920T5 (da) * | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| US12403181B2 (en) | 2018-08-13 | 2025-09-02 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| US11492384B2 (en) | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
| MA54195A (fr) | 2018-11-08 | 2022-02-16 | Synthorx Inc | Conjugués d'interleukine 10 et leurs utilisations |
| WO2020132368A1 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2020130300A1 (ko) * | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 |
| AU2020206672B2 (en) * | 2019-01-07 | 2025-10-02 | Inhibrx Biosciences, Inc. | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
| KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
| CA3129317A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| CN118852456A (zh) * | 2019-05-29 | 2024-10-29 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| KR20220034115A (ko) * | 2019-06-14 | 2022-03-17 | 큐진 인크. | 암 치료용 신규한 인터루킨-2 변이체 |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| PH12022550326A1 (en) * | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| CN114555632A (zh) | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| CA3150082A1 (en) | 2019-09-10 | 2021-03-18 | Jerod PTACIN | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN114853874B (zh) * | 2019-09-10 | 2024-05-17 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| KR102402276B1 (ko) * | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
| MX2022005983A (es) * | 2019-11-18 | 2022-09-07 | Janssen Biotech Inc | Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos. |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| KR20220139293A (ko) | 2019-12-12 | 2022-10-14 | 일투 파마 | 인터류킨 2 키메라 구축물 |
| JP7755581B2 (ja) * | 2019-12-17 | 2025-10-16 | アムジエン・インコーポレーテツド | 治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト |
| US20210188934A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021140416A2 (en) | 2020-01-10 | 2021-07-15 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides and uses thereof |
| TW202140563A (zh) * | 2020-02-21 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｉｌ－２抗體、其抗原結合片段及其醫藥用途 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| CA3166887A1 (en) | 2020-03-06 | 2021-09-10 | Gilbert BENSIMON | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis |
| PE20221759A1 (es) * | 2020-03-31 | 2022-11-11 | Hanmi Pharm Ind Co Ltd | Nuevos analogos de il-2 inmunoestimuladores |
| CA3168737A1 (en) | 2020-04-21 | 2021-10-28 | Jiaxi WU | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
| US11897930B2 (en) * | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| AR122863A1 (es) * | 2020-07-02 | 2022-10-12 | Inhibrx Inc | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos |
| US20230340054A1 (en) * | 2020-09-01 | 2023-10-26 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| IL302276A (en) | 2020-10-23 | 2023-06-01 | Asher Biotherapeutics Inc | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| EP4255466A1 (en) * | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| AU2022211021A1 (en) | 2021-01-20 | 2023-08-03 | Visterra, Inc. | Interleukin-2 mutants and uses thereof |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| EP4373849A4 (en) * | 2021-07-23 | 2025-08-20 | Merck Sharp & Dohme Llc | IL-2 MUTEINS FOR THE TREATMENT OF CANCER OR INFECTION |
| CN113831402A (zh) * | 2021-07-30 | 2021-12-24 | 西安龙腾景云生物科技有限公司 | 一种人白细胞介素2变体及其用途 |
| MX2024004291A (es) | 2021-10-06 | 2024-06-28 | Iltoo Pharma | Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados. |
| CA3238574A1 (en) | 2021-12-01 | 2023-06-08 | Gregory Babcock | Methods of using interleukin-2 agents |
| CN114349843B (zh) * | 2022-01-18 | 2024-05-14 | 浙江博锐生物制药有限公司 | 白细胞介素-2衍生物及其制备方法和应用 |
| CA3245295A1 (en) * | 2022-03-03 | 2025-06-13 | Hainan Simcere Pharmaceutical Co Ltd | Pharmaceutical Composition of Il2 Antibody-Mutant FC Block Fusion Protein and its Use |
| KR20250039519A (ko) | 2022-06-16 | 2025-03-20 | 세파론 엘엘씨 | 항-pd-1 항체-약화된 il-2 면역접합체 및 그의 용도 |
| CA3265946A1 (en) | 2022-09-12 | 2024-03-21 | Univ Sorbonne | INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS |
| WO2024103860A1 (zh) * | 2022-11-18 | 2024-05-23 | 南京诺艾新生物技术有限公司 | 受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途 |
| IL319951A (en) | 2022-11-30 | 2025-05-01 | Integral Molecular Inc | Antibodies targeting claudin 6, including its bispecific formats |
| WO2024121173A1 (en) | 2022-12-05 | 2024-06-13 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
| AU2024207151A1 (en) | 2023-01-09 | 2025-06-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025221954A1 (en) | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| WO2000018938A1 (en) | 1998-09-29 | 2000-04-06 | Pioneer Hi-Bred International, Inc. | Mar/sar elements flanking rsyn7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CN1938428A (zh) | 2003-11-12 | 2007-03-28 | 先灵公司 | 多基因表达的质粒系统 |
| AU2005227263A1 (en) * | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| US20060069515A1 (en) * | 2004-09-30 | 2006-03-30 | International Business Machines Corporation | Method and system for protein folding trajectory analysis using patterned clusters |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| MX2011007647A (es) * | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| HK1220376A1 (zh) * | 2013-03-15 | 2017-05-05 | Angelica Therapeutics, Inc. | 修饰的毒素 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| EP3482766B1 (en) * | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2016
- 2016-05-04 KR KR1020247024111A patent/KR20240115933A/ko not_active Ceased
- 2016-05-04 WO PCT/US2016/030843 patent/WO2016164937A2/en not_active Ceased
- 2016-05-04 CN CN202210486963.1A patent/CN115073581A/zh active Pending
- 2016-05-04 KR KR1020257029040A patent/KR20250133490A/ko active Pending
- 2016-05-04 CN CN201680033372.1A patent/CN109071623B/zh active Active
- 2016-05-04 JP JP2017553119A patent/JP7422480B2/ja active Active
- 2016-05-04 NZ NZ775714A patent/NZ775714A/en unknown
- 2016-05-04 KR KR1020177032587A patent/KR102687530B1/ko active Active
- 2016-05-04 EP EP16726999.2A patent/EP3280725B1/en active Active
- 2016-05-04 EP EP20190744.1A patent/EP3808764A1/en active Pending
-
2021
- 2021-06-09 JP JP2021096449A patent/JP2021153593A/ja active Pending
-
2023
- 2023-06-29 JP JP2023106755A patent/JP7649349B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512151A5 (enExample) | ||
| JP2023134534A5 (enExample) | ||
| Hernandez et al. | Engineering IL-2 for immunotherapy of autoimmunity and cancer | |
| Ferreira et al. | Next-generation regulatory T cell therapy | |
| Roark et al. | Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing γδ T cells | |
| Huang et al. | Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35 | |
| Elinav et al. | Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor | |
| Carmenate et al. | Human IL-2 mutein with higher antitumor efficacy than wild type IL-2 | |
| JP2020500525A (ja) | 対合が改善されたｔ細胞受容体ｔ細胞 | |
| JPH07508179A (ja) | ヒトインターロイキン−１３ | |
| Kim et al. | Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein | |
| KR20160010466A (ko) | Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리 | |
| EP1809669A2 (en) | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents | |
| JP2025106233A5 (enExample) | ||
| US11462297B2 (en) | Selective peptide antagonists | |
| Hasan et al. | Defining a T-cell epitope within HSP 65 in recurrent aphthous stomatitis | |
| CN114901678A (zh) | 肽-mhc ii蛋白构建体及其用途 | |
| Karlen et al. | Biological and molecular characteristics of interleukin-5 and its receptor | |
| Guo et al. | Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region | |
| CN107207622B (zh) | Hla-b27同二聚体用于癌症治疗的用途 | |
| CN108640991A (zh) | 抗人白介素17a单克隆抗体及其应用 | |
| WO2022226054A2 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
| CN114901684B (zh) | 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子 | |
| Baker et al. | Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics | |
| JPWO2019210078A5 (enExample) |